{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-046890","form_type":"8-K","ticker":"SCLX","cik":"0001820190","company_name":"Scilex Holding Co","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.692320+00:00","generated_at":"2026-06-05T12:36:46.052515+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Scilex Pharma settles Virpax litigation for $3.5M upfront, $2.5M later, plus royalties on three drugs","bullets":["Virpax to pay $3.5M by March 1, 2024 and $2.5M by July 1, 2024 to settle the lawsuit.","Royalties of 6% of annual net sales on Epoladerm, Probudur, and Envelta if ever sold.","Mutual release with Virpax; litigation against former President Anthony Mack continues.","Definitive settlement agreement due by March 1, 2024; term sheet binding if not signed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-046890","json":"https://secwatch.observer/filing/0001193125-24-046890.json","markdown":"https://secwatch.observer/filing/0001193125-24-046890.md","text":"https://secwatch.observer/filing/0001193125-24-046890.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1820190/000119312524046890/0001193125-24-046890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1820190/000119312524046890/d795466d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:36:46.052515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c8fb6cd04e20a74cf52e030c22a8e774666a9df8","claim":"Scilex Holding Co entered into Settlement Term Sheet with Virpax Pharmaceuticals, Inc. valued at (i) $3.5 million by March 1, 2024 (the “Initial Payment”); (ii) $2.5 million by July 1, 2024 and (ii (effective 2024-02-26).","evidence_excerpt":"On February 26, 2024, the Plaintiffs and Virpax entered into a term sheet regarding a mutual release and settlement agreement (the “Settlement Term Sheet”), pursuant to which the parties have agreed to enter a definitive settlement agreement by or before March 1, 2024 to resolve their ongoing disputes and provide for, among other things, that Virpax will be obligated to make the following payments to the Company to settle the Action: (i) $3.5 million by March 1, 2024 (the “Initial Payment”); (ii) $2.5 million by July 1, 2024 and (iii) to the extent any of the following drug candidates are ever sold, royalty payments of (a) 6% of annual Net Sales (as defined therein) of Epoladerm; (b) 6% of annual Net Sales of Probudur and (c) 6% of annual Net Sales of Envelta.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1820190/000119312524046890/0001193125-24-046890-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"settlement"},{"label":"Counterparty","value":"Virpax Pharmaceuticals, Inc."},{"label":"Value","value":"(i) $3.5 million by March 1, 2024 (the “Initial Payment”); (ii) $2.5 million by July 1, 2024 and (ii"},{"label":"Effective","value":"2024-02-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}